ATE290882T1 - Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält - Google Patents

Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält

Info

Publication number
ATE290882T1
ATE290882T1 AT02703127T AT02703127T ATE290882T1 AT E290882 T1 ATE290882 T1 AT E290882T1 AT 02703127 T AT02703127 T AT 02703127T AT 02703127 T AT02703127 T AT 02703127T AT E290882 T1 ATE290882 T1 AT E290882T1
Authority
AT
Austria
Prior art keywords
quinazolinaminine
vinorelbine
carboplatin
paclitaxel
combination
Prior art date
Application number
AT02703127T
Other languages
English (en)
Inventor
Karen Elizabeth Lackey
Neil Spector
Edgar Raymond Wood Iii
Wenle Xia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE290882T1 publication Critical patent/ATE290882T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
    • C23C16/22—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of inorganic material, other than metallic material
    • C23C16/30—Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
    • C23C16/40—Oxides
    • C23C16/401—Oxides containing silicon
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/02104—Forming layers
    • H01L21/02107—Forming insulating materials on a substrate
    • H01L21/02109—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates
    • H01L21/02112—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer
    • H01L21/02123—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer the material containing silicon
    • H01L21/02126—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer the material containing silicon the material containing Si, O, and at least one of H, N, C, F, or other non-metal elements, e.g. SiOC, SiOC:H or SiONC
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
    • H01L21/314—Inorganic layers
    • H01L21/316—Inorganic layers composed of oxides or glassy oxides or oxide based glass
    • H01L21/31604—Deposition from a gas or vapour
    • H01L21/31633—Deposition of carbon doped silicon oxide, e.g. SiOC
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Metallurgy (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Power Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02703127T 2001-01-16 2002-01-14 Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält ATE290882T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26240201P 2001-01-16 2001-01-16
PCT/US2002/001130 WO2002056912A2 (en) 2001-01-16 2002-01-14 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent

Publications (1)

Publication Number Publication Date
ATE290882T1 true ATE290882T1 (de) 2005-04-15

Family

ID=22997342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02703127T ATE290882T1 (de) 2001-01-16 2002-01-14 Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält

Country Status (8)

Country Link
US (6) US7141576B2 (de)
EP (1) EP1353693B1 (de)
JP (1) JP4458746B2 (de)
AT (1) ATE290882T1 (de)
AU (1) AU2002236765A1 (de)
DE (1) DE60203260T2 (de)
ES (1) ES2236481T3 (de)
WO (1) WO2002056912A2 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300052A9 (en) * 1997-05-21 2011-12-08 Olsen Gary A Particulate matter and methods of obtaining same from a kraft waste reclamation
US20080219912A1 (en) * 2007-03-06 2008-09-11 Gary Allen Olsen Particulate matter and methods of obtaining same from a kraft waste reclamation
CA2238292A1 (en) * 1997-05-21 1998-11-21 S & S Lime, Inc. Method of obtaining and using particulate calcium carbonate
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1353693B1 (de) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
JP2005534623A (ja) * 2002-04-08 2005-11-17 スミスクライン ビーチャム コーポレーション Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
MXPA06001599A (es) 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
WO2005046678A1 (en) * 2003-11-07 2005-05-26 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2005251722B2 (en) * 2004-06-03 2009-11-12 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2005251769B2 (en) * 2004-06-04 2008-10-02 Novartis Ag Cancer treatment method
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
ES2426007T3 (es) * 2004-12-17 2013-10-18 Smithkline Beecham (Cork) Limited Método para el tratamiento del cáncer
CN101115747A (zh) 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
ES2601503T3 (es) 2005-04-19 2017-02-15 Novartis Ag Composición farmacéutica
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
WO2007058852A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
US20080269131A1 (en) * 2005-11-10 2008-10-30 Smithkline Beecham Corporation Inhibitors of Akt Activity
US20090005406A1 (en) 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method
JP2009528386A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
JP2010510990A (ja) * 2006-11-28 2010-04-08 スミスクライン ビーチャム （コーク） リミテッド 癌の治療方法
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
JP2010513321A (ja) * 2006-12-22 2010-04-30 ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
EP2117313A4 (de) * 2007-01-12 2011-04-27 Biogen Idec Inc Pharmazutika, zusammensetzungen und verfahren zu ihrer herstellung und verwendung
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US8288312B2 (en) 2007-03-06 2012-10-16 S&S Lime, Inc. Particulate matter and methods of obtaining same from a Kraft waste reclamation
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
WO2009032651A1 (en) * 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
ES2399774T3 (es) 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
EP2211855A4 (de) * 2007-10-09 2011-12-07 Univ Pennsylvania Thrombopoetin-rezeptor-agonist (tpora) vernichtet akute myeloische leukämiezellen beim menschen
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2009079541A1 (en) * 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline ditosylate anhydrate forms
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
UA127472C2 (uk) 2008-03-18 2023-09-06 Дженентек, Інк. Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2009140144A1 (en) * 2008-05-15 2009-11-19 Teva Pharmaceutical Industries Ltd. Forms of crystalline lapatinib and processes for preparation thereof
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
EP2158912A1 (de) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
EP3100745B1 (de) 2009-02-05 2018-04-18 Immunogen, Inc. Neuartige benzodiazepinderivate
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
WO2010118013A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
KR102012398B1 (ko) 2009-11-05 2019-08-20 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
EP2526102B1 (de) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III PI3-kinase-inhibitoren
EP2533810B1 (de) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20-antikörper und ihre verwendung
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011116634A1 (en) * 2010-03-23 2011-09-29 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
NZ602635A (en) 2010-03-29 2014-12-24 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
CN103108648A (zh) * 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
MY183977A (en) 2011-02-15 2021-03-17 Immunogen Inc Cytotoxic benzodiazepine derivatives
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
EP2524918A1 (de) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazinderivate als Kinase Inhibitoren
MX349366B (es) 2011-05-19 2017-07-26 Centro Nac De Investigaciones Oncologicas (Cnio) Compuestos novedosos.
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN103483324B (zh) * 2012-06-12 2016-03-30 人福医药集团股份公司 拉帕替尼的新制备方法
SI2870157T1 (en) 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S.A. SELECTIVE PI3K-DELTA INHIBITORS
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
AU2017321973A1 (en) 2016-09-02 2019-03-07 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
WO2019161263A1 (en) * 2018-02-16 2019-08-22 Ohio State Innovation Foundation Lipid-surfactant nanoparticles for drug delivery and methods of making and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
IL122782A (en) 1995-07-21 2003-03-12 Gruppe Constantia Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
KR100561788B1 (ko) * 1996-03-12 2006-09-20 피지-티엑스엘 컴파니,엘.피. 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2000072749A (ja) 1998-08-24 2000-03-07 Mitsui Chemicals Inc キノリン誘導体を用いるアポトーシス誘導剤
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
EP1193258A4 (de) 1999-06-22 2002-11-13 Takeda Chemical Industries Ltd Verfahren zur herstellung von imidazolderivaten
WO2001004111A1 (en) * 1999-07-09 2001-01-18 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
DE19947028A1 (de) * 1999-09-30 2001-04-12 Siemens Ag Thyristor mit Spannungsstoßbelastbarkeit in der Freiwerdezeit
CZ300945B6 (cs) 2000-06-30 2009-09-23 Glaxo Group Limited Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu
EP1353693B1 (de) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält

Also Published As

Publication number Publication date
EP1353693B1 (de) 2005-03-16
US20120058113A1 (en) 2012-03-08
US8444988B2 (en) 2013-05-21
ES2236481T3 (es) 2005-07-16
DE60203260T2 (de) 2006-02-02
US20110312982A1 (en) 2011-12-22
DE60203260D1 (de) 2005-04-21
US7141576B2 (en) 2006-11-28
JP4458746B2 (ja) 2010-04-28
US20150366868A1 (en) 2015-12-24
EP1353693A2 (de) 2003-10-22
WO2002056912A2 (en) 2002-07-25
JP2004523522A (ja) 2004-08-05
WO2002056912A3 (en) 2003-05-22
AU2002236765A1 (en) 2002-07-30
US20100249160A1 (en) 2010-09-30
US20070148261A1 (en) 2007-06-28
US20040053946A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ATE290882T1 (de) Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
BRPI0412798A (pt) uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
EA200401318A1 (ru) Производные хинолинона
CY1114359T1 (el) Παραγοντας κατα ογκων περιλαμβανων τον αναστολεα αποακετυλασης ιστονης fk228 kai ton αναστολεα τοποϊσομερασης ιι δοξορουβικινη
MY127369A (en) Quinazoline derivatives
BR0109198A (pt) Emplastro com filtro ultravioleta
AR027355A1 (es) Acidos tiazolidincarboxilicos
MY129809A (en) Quinazoline derivatives
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
TR200500745T2 (tr) Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DE60322412D1 (de) Pharmazeutische feste Dispersionen von Modafinil-Verbindungen
ATE448232T1 (de) Substituierte heterozyklen
AR037346A1 (es) Terapia de combinacion
ID29780A (id) Bahan-bahan elektroluminesen
NO20050640L (no) Rutenium anticancer komplekser
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
ATE376824T1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
NO20024076L (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties